Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2011 2
2012 3
2013 4
2014 4
2015 7
2016 3
2017 1
2018 3
2019 2
2020 3
2021 1
2022 5
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. Wainberg ZA, et al. Among authors: teixeira a. Lancet Oncol. 2022 Nov;23(11):1430-1440. doi: 10.1016/S1470-2045(22)00603-9. Epub 2022 Oct 14. Lancet Oncol. 2022. PMID: 36244398 Clinical Trial.
The landscape for lipid-nanoparticle-based genomic medicines.
Verma M, Ozer I, Xie W, Gallagher R, Teixeira A, Choy M. Verma M, et al. Among authors: teixeira a. Nat Rev Drug Discov. 2023 May;22(5):349-350. doi: 10.1038/d41573-023-00002-2. Nat Rev Drug Discov. 2023. PMID: 36627441 No abstract available.
Use of some cost-effective technologies for a routine clinical pathology laboratory.
Vázquez M, Anfossi L, Ben-Yoav H, Diéguez L, Karopka T, Della Ventura B, Abalde-Cela S, Minopoli A, Di Nardo F, Shukla VK, Teixeira A, Tvarijonaviciute A, Franco-Martínez L. Vázquez M, et al. Among authors: teixeira a. Lab Chip. 2021 Nov 9;21(22):4330-4351. doi: 10.1039/d1lc00658d. Lab Chip. 2021. PMID: 34664599 Review.
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
Wainberg ZA, Kang YK, Lee KW, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Zahlten-Kümeli A, Taylor K, Enzinger PC. Wainberg ZA, et al. Among authors: teixeira a. Gastric Cancer. 2024 Feb 3. doi: 10.1007/s10120-024-01466-w. Online ahead of print. Gastric Cancer. 2024. PMID: 38308771
The Wnt Antagonist Dickkopf-1 Promotes Pathological Type 2 Cell-Mediated Inflammation.
Chae WJ, Ehrlich AK, Chan PY, Teixeira AM, Henegariu O, Hao L, Shin JH, Park JH, Tang WH, Kim ST, Maher SE, Goldsmith-Pestana K, Shan P, Hwa J, Lee PJ, Krause DS, Rothlin CV, McMahon-Pratt D, Bothwell AL. Chae WJ, et al. Among authors: teixeira am. Immunity. 2016 Feb 16;44(2):246-58. doi: 10.1016/j.immuni.2016.01.008. Epub 2016 Feb 9. Immunity. 2016. PMID: 26872695 Free PMC article.
40 results